4//SEC Filing
Astor Andrew 4
Accession 0000914190-19-000213
CIK 0001196298other
Filed
Jun 13, 8:00 PM ET
Accepted
Jun 14, 12:35 PM ET
Size
14.1 KB
Accession
0000914190-19-000213
Insider Transaction Report
Form 4
NEPHROS INCNEPH
Astor Andrew
Chief Financial Officer
Transactions
- Purchase
Common Stock
2019-06-14$0.64/sh+35,000$22,400→ 532,903 total
Holdings
- 133,333
Warrants (right to buy)
Exercise: $0.30From: 2017-03-17Exp: 2022-03-17→ Common Stock (133,333 underlying) - 289,785
Stock Option (right to buy)
Exercise: $0.46Exp: 2027-02-13→ Common Stock (289,785 underlying) - 209,355
Stock Option (right to buy)
Exercise: $0.29Exp: 2027-05-01→ Common Stock (209,355 underlying) - 200,000
Stock Option (right to buy)
Exercise: $0.65Exp: 2028-12-19→ Common Stock (200,000 underlying) - 50,000
Stock Option (right to buy)
Exercise: $0.50Exp: 2027-12-20→ Common Stock (50,000 underlying)
Footnotes (6)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.62 to $0.65. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]Includes 44,111 shares of restricted stock that vest on 6/14/19.
- [F3]On 2/13/17, the Reporting Person was granted an option to purchase up to 579,571 shares of common stock of the Company. Options to purchase 72,446 shares vested on 2/13/18; options to purchase 217,339 shares vest quarterly in 12 equal amounts commencing on 5/13/18; options to purchase 115,914 shares will vest, if ever, upon approval of listing of the Company's common stock on the Nasdaq Stock Market, New York Stock Exchange or such other national securities exchange approved by the Board; options to purchase 57,957 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $6,000,000; and options to purchase 115,914 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $10,000,000.
- [F4]On 5/1/17, the Reporting Person was granted an option to purchase up to 418,709 shares of common stock of the Company. Options to purchase 52,339 shares vested on 5/1/18; options to purchase 157,016 shares vest quarterly in 12 equal amounts commencing on 7/1/18; options to purchase 41,871 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $6,000,000; options to purchase 83,742 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $10,000,000; and options to purchase 83,742 shares will vest, if ever, upon approval of listing of the Company's common stock on the Nasdaq Stock Market, New York Stock Exchange or such other national securities exchange approved by the Board.
- [F5]On 12/20/17, the Reporting Person was granted an option to purchase 50,000 shares of common stock of the Company. Options to purchase 12,500 shares vested on 12/20/18 and options to purchase 37,500 shares vest quarterly in 12 equal amounts commencing on 3/20/19.
- [F6]On 12/19/18, the Reporting Person was granted an option to purchase 200,000 shares of common stock of the Company. Options to purchase 50,000 shares vest on 12/19/19 and options to purchase 150,000 shares vest quarterly in 12 equal amounts commencing on 3/19/20.
Documents
Issuer
NEPHROS INC
CIK 0001196298
Entity typeother
Related Parties
1- filerCIK 0001698052
Filing Metadata
- Form type
- 4
- Filed
- Jun 13, 8:00 PM ET
- Accepted
- Jun 14, 12:35 PM ET
- Size
- 14.1 KB